Monon Bioventures

What Monon Bioventures does

Monon Bioventures, LLC (MBV) is a privately held life sciences accelerator founded in 2015 and headquartered in Fishers/Indianapolis, Indiana. The company partners with academic investigators and research institutions — notably Purdue University, Indiana University School of Medicine, and Nationwide Children's Hospital — to translate early-stage discoveries into investable preclinical and clinical assets. MBV provides funding strategy, business leadership, program management, and grant navigation (primarily NIH SBIR/STTR), while its investigator partners retain focus on the underlying science. The company operates as a portfolio platform rather than a single-product entity, with named programs including Scioto Biosciences (microbiome/biofilm platform with an NEC indication), Arrhythmotech (patent-pending neuECG SKNA biomarker device and software), the ear-in-a-dish stem cell hearing-loss model, a Purdue-derived soluble glucagon derivative for hypoglycemia rescue, a cell-based Type 1 diabetes program, a glioblastoma therapy, and a bioengineered anti-cancer chewing gum.

Name

Monon Bioventures

Legal name

Monon Bioventures, LLC

Website

https://mononbioventures.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Monon Bioventures is a privately held Indiana-based life sciences accelerator that partners with academic investigators to translate early-stage research into investable preclinical and clinical assets, operating a portfolio of spinouts and SBIR/STTR-funded programs across microbiome, neurology, metabolic, and oncology indications.

Ownership category

akta.pro rank

Headquarters

HQ city

Fishers

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Grant-funded program development (SBIR/STTR): Monon Bioventures secures NIH SBIR/STTR grants (typically around $250,000 each, with phase II awards up to $1.4M-$1.5M) to fund pre-clinical development of investigator assets. Funding flows into MBV-led programs and collaborations.
2. Venture competition prize money: Spinouts such as Scioto Biosciences have won BioCrossroads New Venture Competition prize money ($25,000) to fund pre-clinical phases; provides validation as well as capital.
3. Equity / spinout value creation: MBV operates an accelerator model where it helps form spinout companies (e.g., Scioto Biosciences expected to be the first spinout) and is positioned to benefit from follow-on capital events with angel investors, venture capitalists and strategic corporate partners.
4. Collaborative network development services: Through partnership with Celdara Medical and Virtici, MBV shares externalization of search, evaluation, de-risking and preclinical development functions for biotech and pharma partners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Monon Bioventures is a privately held life sciences accelerator that partners with world-class academic investigators and research institutions to translate early-stage scientific discoveries into investable pre-clinical and clinical assets. The company provides funding strategy, business leadership, program management, and a nationwide collaborative development network, typically securing NIH SBIR/STTR grants to de-risk investigator assets before exposing them to angel, venture, or strategic capital. It has six active programs across microbiome therapeutics, digital biomarkers, stem-cell models, glucagon analogs, and other modalities, and forms spinout companies (e.g., Scioto Biosciences, Arrhythmotech) to advance specific assets toward the clinic.

Product overview

Monon Bioventures, LLC (MBV) is a privately held life sciences "accelerator" rather than a single unified software product. Its core offering is a services-plus-portfolio platform that partners with academic investigators and research institutions (e.g., Indiana University School of Medicine, Purdue University, Nationwide Children's Hospital) to translate early-stage discoveries into investable clinical assets, providing funding strategy, business leadership, and program management. Its named portfolio consists of spinout sub-brands and preclinical programs, including: (1) Scioto Biosciences and its Activated Therapeutic Bacterial Platform (probiotic / microbiome therapeutics with an initial NEC program); (2) Arrhythmotech and its neuECG(TM) continuous digital biomarker medical device + software platform; (3) the "Ear-in-a-Dish" stem cell hearing-loss model; (4) a Purdue-derived soluble glucagon derivative program for hypoglycemia rescue kits; (5) a Purdue cell-based therapy for Type 1 diabetes; (6) a Purdue glioblastoma therapy funded by an SBIR grant; and (7) bioengineered chewing gum targeting cancer-linked oral microbes. Together these programs form a multi-asset accelerator pipeline rather than a single integrated product.

Differentiator

Problem solved

Functional benefit

Brands

• Scioto Biosciences: A Monon Bioventures initiative developing medicines to support and improve microbiome health through a novel microparticle platform leveraging probiotic biofilms; first expected spinout from MBV.
• Arrhythmotech

Products and services

• Scioto Biosciences (Activated Therapeutic Bacterial Platform) A Monon Bioventures sub-brand spinout developing microbiome health medicines via a novel formulation that combines beneficial bacteria with polysaccharide microspheres to induce biofilm formation and enable non-spore-forming bacteria to survive passage through the gastrointestinal system; initial lead indication is a probiotic biologic for necrotizing enterocolitis (NEC) in premature infants.
• Arrhythmotech (neuECG continuous digital biomarker platform) Monon Bioventures-affiliated medical device and software platform (neuECG) that enables direct, non-invasive measurement and interpretation of changes in sympathetic tone via skin-surface SKNA (sympathetic nerve activity), creating a continuous digital biomarker applicable to clinical (chronic and acute pain, epilepsy, sleep apnea, hypertension, sudden cardiac death, atrial fibrillation) and wearable/consumer (stress, human performance, anxiety, fatigue, mindfulness) applications.
• Ear-in-a-Dish Stem Cell Model Program Preclinical research program developed with Dr. Karl Koehler at Indiana University School of Medicine that programs stem cells to turn into functional inner-ear tissue, growing a functional mouse ear in roughly 60 days; used as a scalable drug-testing model to evaluate pharmaceutical candidates for preventing hearing loss, with potential future scale-up to thousands of ears and longer-term surgical implant applications.
• Improved Glucagon Hypoglycemia Rescue Kit Program

Quantifiable outcome

• Secured $1.4 million NIH SBIR Phase I/II grant for diabetes hypoglycemia rescue kit development
• +4 more outcomes

Named customers3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

• Purdue University (glioblastoma therapy program)coreStrategic or Co-development Partner · 22 September 2022Monon Bioventures received an SBIR grant to develop a glioblastoma therapy created at Purdue. The same article mentions a bioengineered chewing gum that reduces oral microbes linked to cancer as an adjacent MBV program.
• Purdue University (Elizabeth Topp, Industrial and Physical Pharmacy)coreStrategic or Co-development Partner · 7 May 2019Collaboration funded by NIH SBIR Phase I/II grant (up to $1.4M) to develop better hypoglycemia rescue kits via novel soluble/stable glucagon derivatives. CEO Joseph Trebley received his PhD from Purdue's College of Pharmacy. Purdue Research Foundation Office of Technology Commercialization is supporting development and patenting.
• Nationwide Children's Hospital (Columbus, OH)coreStrategic or Co-development Partner · 30 October 2016Research collaboration that produced the underlying science for Scioto Biosciences' probiotic platform. The startup's first technology is a biologic that battles necrotizing enterocolitis (NEC) in premature infants, with plans to spin out as MBV's first spinout company.
• Indiana University School of Medicine (Dr. Karl Koehler)coreStrategic or Co-development Partner · 5 May 2016MBV partnered with Dr. Karl Koehler at Indiana University School of Medicine to develop the first "ear-in-a-dish" stem cell model for studying and treating hearing loss; able to grow a functional mouse ear from stem cells in 60 days, with plans to scale to thousands of ears for drug testing.
• Celdara MedicalflagshipStrategic or Co-development Partner · 9 November 2015Co-announced the formation of the first collaborative nationwide network for the development of early-stage biotechnologies together with Virtici and MBV. Celdara and MBV share dealflow, best practices, and externalize search, evaluation, derisking and preclinical development functions. Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, with locations in Lebanon, NH and New York, NY.
• VirticiflagshipStrategic or Co-development Partner · 9 November 2015Co-announced with Celdara Medical and MBV the formation of the first collaborative nationwide network for development of early-stage biotechnologies. Virtici's President and CEO is Neil Fanger, Ph.D. The three firms share best practices, dealflow and an efficient business model for driving medical innovations from bench to bedside.
• Rose-Hulman VenturesminorImplementation/ SI/ Consulting PartnerArrhythmotech (an MBV initiative) collaborated with Rose-Hulman Ventures to develop a beta version of the neuECG device/software platform, which is being tested at Indiana University and other top-ranked research institutions.
• Mayo ClinicminorStrategic or Co-development PartnerArrhythmotech collaborators at Mayo Clinic (along with Indiana University and Cedars-Sinai Medical Center) carried out the initial prototype testing on the neuECG device.
• Cedars-Sinai Medical CenterminorStrategic or Co-development PartnerCollaborator on Arrhythmotech neuECG initial prototype testing, alongside Indiana University and Mayo Clinic.
• Purdue Research Foundation Office of Technology CommercializationcoreImplementation/ SI/ Consulting PartnerSupports economic development and tech transfer for Purdue University. Working with Topp and MBV to develop and patent glucagon derivatives for improved glucagon solutions. Operates one of the most comprehensive technology transfer programs among leading research universities in the U.S.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Celdara Medical: Celdara Medical is MBV's closest peer and explicit partner — both operate as early-stage life sciences accelerators that originate and de-risk academic biotech assets. Founded in 2008 in Lebanon, NH, Celdara shares dealflow with MBV and Virtici under the same nationwide collaborative network.
• Virtici: Virtici is the third member of the nationwide early-stage biotech development network alongside Celdara and MBV. Operates as an accelerator that builds and spins out therapeutic assets from academic research with shared dealflow and externalized preclinical functions.
• Accelerator Corp: Accelerator Corp is a Seattle-based life sciences accelerator that partners with academic institutions to identify, fund, and develop early-stage biotechnology assets — a closely analogous operating model to MBV's accelerator-plus-spinout approach.

Broad incumbents

• Atlas Venture: Atlas Venture is a well-established biotech venture firm that builds companies from academic science, analogous in mission to MBV but with significantly more capital, broader therapeutic reach, and a longer track record of IPOs and M&A.
• ARCH Venture Partners: ARCH Venture Partners is a large, established early-stage biotech VC that originates and funds academic spinouts — broader and deeper-pocketed than MBV but operating in the same "bench to venture" translational space.
• Flagship Pioneering: Flagship Pioneering operates a platform for creating and developing first-in-class biotechnologies, comparable to MBV's role as an originator and developer of platform assets, but at vastly greater scale (creator of Moderna).

Regional players

• Indiana Center for Biomedical Innovation (ICBI): ICBI is the Indianapolis-based life sciences incubator where MBV physically operates. It provides fully equipped lab space and animal facilities to early-stage life sciences startups — a complementary regional infrastructure peer in the same Indiana ecosystem.
• BioCrossroads: BioCrossroads is the Indiana life sciences initiative that ran the New Venture Competition Scioto Biosciences won in 2016. Comparable as a regional capital-and-community catalyst for early-stage biotech, though it is more of an ecosystem convener than a direct asset developer.

Others

• Purdue Research Foundation Office of Technology Commercialization: Purdue Research Foundation's tech transfer office is MBV's partner on multiple SBIR-funded programs (glucagon derivatives, glioblastoma). Functions as the upstream supplier of academic IP into MBV's accelerator pipeline rather than a direct competitor.
• Indiana University Research and Technology Corp (IURTC): IURTC is the technology transfer arm of Indiana University where MBV CEO Joe Trebley previously led startup support. It is an upstream supplier of academic IP (e.g., the ear-in-a-dish program) rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/monon-bioventures-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monon Bioventures